Late Pulmonary Toxicity Associated With Everolimus in a Renal Transplant Patient and Review of the Literature.
Arzu Velioğlu, Emel Eryüksel, Çağatay Çimşit, Serhan Tuğlular, Çeti̇n Özener
Abstract
Arzu Velioğlu, Emel Eryüksel, Çağatay Çimşit, Serhan Tuğlular, Çeti̇n Özener
Abstract
The use of inhibitors of mammalian target of rapamycin is associated with adverse pulmonary effects. Although sirolimus-related pneumonitis has been well described, reports on pneumonitis with everolimus are scarce. We report a case of everolimus-induced pneumonitis in a renal transplant recipient 5 years after initiation of everolimus treatment, and we also review the literature regarding everolimus-induced pneumonitis in renal transplant patients.
OpenAlex reports 6 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
The use of inhibitors of mammalian target of rapamycin is associated with adverse pulmonary effects. Although sirolimus-related pneumonitis has been well described, reports on pneumonitis with everolimus are scarce. We report a case of everolimus-induced pneumonitis in a renal transplant recipient 5 years after initiation of everolimus treatment, and we also review the literature regarding everolimus-induced pneumonitis in renal transplant patients.
Key concepts: Everolimus, Pneumonitis, Medicine, Renal transplant, Sirolimus, Interstitial pneumonitis, Adverse effect, Internal medicine